TOP HEADLINES

Featured Story

Scientists uncover new drug delivery method using nanosecond lasers and carbon nanotubes

Engineers and cell biologists have long used pulsed lasers to stimulate cells for gene transfection, drug injection or the regulation of gene expression. Now, Japanese scientists uncovered a new, potentially less-expensive method of delivering drugs and manipulating genes of individual cells by pairing nanosecond laser energy with carbon nanotubes.

Alnylam receives more good news on the IP front

Alnylam Pharmaceuticals received a Notice of Allowance from the U.S. Patents and Trademarks Office for an application granting the company new claims to RNA interference (RNAi) medicines.

Hydrogel enables longer graft survival in hand, leg transplant patients

Researchers successfully delivered the immunosuppressant tacrolimus in a self-assembled hydrogel, enabling localized therapy in patients receiving a tissue graft transplant of the leg, hand or face.

Arrowhead updates TheStreet on clinical trial results of RNAi candidate for hepatitis B

Arrowhead Research reported on Aug. 12 that patients in its Phase II clinical trial of the ARC-520 RNA interference candidate for hepatitis B had a "similar" knockdown to those reported in primate studies. The stock price fell at the very end of the trading day to close at $12.00 from an opening-day price of $13.00.

Can insect venom be harnessed to fight cancer?

A bioengineering professor says he has developed nanoparticles that can carry cancer-fighting insect toxins directly to tumors, sparing the rest of the body from nasty side effects, including damage to the heart, bleeding underneath the skin and unwanted clotting.

MORE NEWS

From Our Sister Sites

FierceCRO

Biotech Otologic Pharmaceuticals has chosen North Carolina's PharPoint Research to run an early trial of its lead candidate, a treatment for hearing loss.

FierceMedicalDevices

The U.S. Food and Drug Administration has picked up the pace on novel medical device approvals, but this year still may not hit levels seen in 2011 and 2012. During the first six months of 2014, the agency granted 17 premarket approvals, way up from 23 for the entirety of 2013.